FDA warns ABBE Laboratories over manufacturing failures for over-the-counter topical drugs, including ingredient testing.
What happened
FDA inspected ABBE Laboratories’ drug manufacturing facility in Farmingdale, New York, from February 24 to 27, 2025. FDA found that the firm makes and repackages over-the-counter topical liquids and ointments without adequate ingredient identity testing, including for propylene glycol and glycerin, which are at higher risk of diethylene glycol or ethylene glycol contamination. FDA also found inadequate cleaning validation and documentation, missing process validation, and inadequate quality unit oversight, and it cited repeat violations from a 2018 inspection.
What FDA found
Failed to test each incoming ingredient lot for identity, including propylene glycol and glycerin, and relied on supplier certificates without establishing their reliability.
21 CFR 211.84(d)(1) and (2)Failed to show cleaning procedures remove contaminants from shared equipment and stopped documenting cleaning activities around 2020.
21 CFR 211.67(b)Failed to provide validation protocols and reports showing manufacturing processes are controlled.
21 CFR 211.100(a)Quality unit lacked adequate procedures and oversight; batch records were incomplete and annual product reviews were not done since at least 2018.
21 CFR 211.22(d)
What FDA wants
FDA tells ABBE to correct the violations promptly and respond in writing within 15 working days with what it has done and how it will prevent recurrence. FDA also asks for DEG and EG test results from retained high-risk component lots, or testing of implicated finished batches, no later than 30 calendar days from the letter date.
Who should pay attention
- brands that buy finished over-the-counter topical drugs from this contract manufacturer
- companies repackaging or distributing OTC liquids and ointments
- quality teams managing glycerin and propylene glycol supplier testing
This is a summary. Read the original letter on fda.gov.